Warner–Lambert

Warner–Lambert was an American pharmaceutical company.

Warner–Lambert
IndustryPharmaceutical
FateAcquired by Pfizer in 2000
Founded1856 (1856)
Philadelphia, Pennsylvania, U.S.
FounderWilliam R. Warner
Defunct2000 (2000)
Headquarters
Morris Plains 
ParentPfizer

History

Formerly two separate entities, the first company was started in 1856, when William R. Warner founded a drug store in Philadelphia. Warner went on to invent a tablet coating process gaining him a place in the Smithsonian Institution. The second half of the name came from Jordan Wheat Lambert, founder of the Lambert Pharmacal Company of St. Louis,[1] famous for Listerine. The two companies merged in 1955, to form Warner–Lambert.

Over the years, the company expanded through many mergers and acquisitions to become an international competitor in several businesses. In 1976, Warner–Lambert took over Parke-Davis, which was founded in Detroit in 1866, by Hervey Parke and George Davis. This was followed by acquisitions of Wilkinson Sword in March 1993, and Agouron Pharmaceuticals in January 1999.[2][3]

Its subsidiary Parke-Davis marketed the antidiabetic drug Rezulin, which had FDA approval from January 1997 to 2000.

In the end of the 1990s, Warner–Lambert formed an alliance with Pfizer to bring its drug Lipitor to market. Lipitor launched in January 1997 to resounding success, reaching $1B in domestic sales within its first twelve months on the market.[4] In February 2000, Pfizer bought Warner Lambert along with all of its subsidiary companies.[5] The headquarters of Warner–Lambert in Morris Plains, New Jersey, subsequently used by Pfizer and Johnson & Johnson, is now being used as the headquarters of Honeywell as of 2018.

References
  1. "Lambert Pharmacal Company". www.rdhinstl.com. Retrieved 2019-06-03.
  2. "COMPANY NEWS; WARNER-LAMBERT ACQUIRES WILKINSON SWORD". www.nytimes.com. 23 March 1993. Retrieved 27 May 2018.
  3. "Warner-Lambert to Acquire Agouron Pharmaceuticals". www.nytimes.com. 27 January 1999. Retrieved 27 May 2018.
  4. Koberstein, Wayne, "Master Launchers", Pharmaceutical Executive, May 1998.
  5. "Pfizer Gets Its Deal to Buy Warner-Lambert for $90.2 Billion". www.nytimes.com. 7 February 2000. Retrieved 27 May 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.